Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer.

Urologic oncology - 1 Jan 2000

van Rhijn Bas W G

Abstract excerpt

Non-muscle-invasive (NMI) bladder cancer (BC) is a chronic disease with varying oncologic outcomes requiring frequent follow-up and repeated treatments. Recurrence (in up to 80%) is the main problem for pTa NMI-BC patients, whereas progression (in up to 45%) is the main threat in pT1 and carcinoma in situ (CIS) NMI-BC. In a recent European Organization for Research and Treatment of Cancer (EORTC) analysis,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neoplasm Grading
Share to Neoplasm Invasiveness
Share to Neoplasm Staging

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Prognosis

Share to Receptor, Fibroblast Growth Factor, Type 3

Share to Sensitivity and Specificity

Share to Urinary Bladder

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 22742564
DOI: 10.1016/j.urolonc.2012.04.002

Genes

NMI
FGFR3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer.PMID 22742564Read ↗

Evolution of Urothelial Bladder Cancer in the Context of Molecular ClassificationsSemantic proximity Read ↗

Novel Gene expression-based Risk Stratification tool predicts recurrence in Non-muscle invasive Bladder cancerSemantic proximity Read ↗

Development and Validation of a Prognostic Nomogram Model for Recurrence of Non-Muscle Invasive Bladder CancerSemantic proximity Read ↗

Novel Gene expression-based Risk Stratification tool predicts recurrence in Non-muscle invasive Bladder cancerSemantic proximity Read ↗

Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer.Semantic proximity Read ↗

Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer.Semantic proximity Read ↗

Molecular Markers Increase Precision of the European Association of Urology Non-Muscle-Invasive Bladder Cancer Progression Risk Groups.Semantic proximity Read ↗

Comprehensive genome-wide association study into multiple recurrence and progression risk in non-muscle invasive bladder cancer.Semantic proximity Read ↗

Greater utility of molecular subtype rather than epithelial-to-mesenchymal transition (EMT) markers for prognosis in high-risk non-muscle-invasive (HGT1) bladder cancer.Semantic proximity Read ↗

Molecular markers in bladder cancer: Novel research frontiersSemantic proximity Read ↗

Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study.Semantic proximity Read ↗

The Role of Immunohistochemistry as a Surrogate Marker in Molecular Subtyping and Classification of Bladder CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.